Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 10/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 10/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | EED | O75530 | 2/20 | 0.37 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.37 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290350 | 0.92 | GABRG2 (0.44) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL4291358 | 0.84 | HCAR1 (0.38) | MAPT | |
| SCHEMBL4291087 | 0.82 | TRPM8 (0.44) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL4284854 | 0.82 | GABRG2 (0.46) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL4282663 | 0.81 | CYP19A1 (0.45) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL4282668 | 0.81 | CYP19A1 (0.45) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL13705063 | 0.81 | CYP19A1 (0.45) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL4282660 | 0.81 | CYP19A1 (0.45) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL4296722 | 0.81 | CYP19A1 (0.45) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL4289354 | 0.81 | CYP19A1 (0.44) | GABRG2GABRB3GABRA5GABRA3GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | GABRG2 3657/4885GABRB3 3110/4885GABRA5 1948/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | GABRG2 3657/4885GABRB3 3110/4885GABRA5 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.